Immuron Limited announced the initiation of several studies designed to add to the growing body of evidence supporting the unique mechanism of action (MOA) of IMM-124E in non-alcoholic steatohepatitis (NASH). The studies will be done in partnership with Sanyal Biotechnology and Duke University. The studies aim to further expound on the pre-clinical and clinical evidence previously gathered on IMM-124E for the treatment of NASH. These studies are expected to run throughout calendar year 2017. IMM-124E is an immunomodulatory therapeutic with broad application across diseases and conditions associated with excess peripheral chronic inflammation. The anti-inflammatory effect of IMM-124E in NASH is supported by the company’s pre-clinical and clinical studies to date, including the outstanding results of the CCl4 liver fibrosis model, demonstrating IMM-124E’s anti-fibrotic effect. In Phase 1 clinical studies, IMM-124 was found to improve liver enzymes, insulin resistance (OGTT and HgbA1c), and dyslipidemia (LDL).